679 results match your criteria: "National Cancer Institute of Naples IRCCS "G. Pascale"[Affiliation]"
Sleep disorders and hyperarousal among patients with endometriosis: A case-control survey study.
Eur J Obstet Gynecol Reprod Biol
September 2024
Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Via Consolare Valeria 1, Contesse, Messina 98125, Italy. Electronic address:
Article Synopsis
- Endometriosis is linked to sleep disorders, and a study investigated the role of hyperarousal in this connection among endometriosis patients compared to a general population control group.
- The study involved 847 women, revealing that those with endometriosis had significantly higher scores on measures of hyperarousal, sleep quality, and insomnia severity.
- The findings suggest that addressing hyperarousal through cognitive behavioral therapy could help improve sleep issues in women with endometriosis.
Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer.
J Transl Med
July 2024
Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Background: Breast cancer manifests as a heterogeneous pathology marked by complex metabolic reprogramming essential to satisfy its energy demands. Oncogenic signals boost the metabolism, modifying fatty acid synthesis and glucose use from the onset to progression and therapy resistant-forms. However, the exact contribution of metabolic dependencies during tumor evolution remains unclear.
View Article and Find Full Text PDFCorrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].
Lancet Reg Health Eur
July 2024
National Cancer Institute, IRCCS Fondazione G.Pascale, Naples, Italy.
[This corrects the article DOI: 10.1016/j.lanepe.
View Article and Find Full Text PDFAnatomical-based classification of dorsolateral parametrectomy for deep endometriosis. Correlation with surgical complications and functional outcomes: A single- center prospective study.
Int J Gynaecol Obstet
December 2024
Unit of Oncological Gynecology, Women's Children's and Public Health Department, IRCCS, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.
Objective: To evaluate complication rate and functional outcomes of nerve-sparing parametrectomy for deep endometriosis in relation to the extension of the surgical procedure, based on recognizable anatomical landmarks.
Methods: This was a prospective single-center study including all patients undergoing parametrectomy for deep endometriosis from September 2020 to June 2023 at our tertiary center. Dorsolateral parametrectomies were divided into parametrectomies medial to the presacral fascia and cranial to the medial rectal artery (superficial parametrectomy), and parametrectomies in which one of the two landmarks was overcome during the surgical procedure, leading to the excision of tissue lateral to the presacral fascia (deep parametrectomy type 1, or DP1) or caudal to the medial rectal artery (DP2).
The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers.
J Exp Clin Cancer Res
July 2024
Department of Research, Diagnosis and Innovative Technologies, UOSD SAFU, IRCCS Regina Elena National Cancer Institute, 00144, Rome, Italy.
Article Synopsis
- Pancreatic cancer is hard to treat because it's often diagnosed at an advanced stage, lacks early symptoms, and has few reliable biomarkers for detection.
- *Recent research shows that interactions between cancer and immune cells in both the tumor micro-environment and distant areas of the body (macro-environment) play a crucial role in tumor growth and immune response.
- *Understanding how these environments interact may lead to new early detection methods and therapies for pancreatic cancer through identifying molecular targets and improving diagnostic biomarkers.
Role of V-Y flap reconstruction in vulvar cancer patients: multicenter retrospective study.
Int J Gynecol Cancer
August 2024
Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Article Synopsis
- The study aimed to evaluate whether using a V-Y reconstructive flap after surgery for vulvar cancer improves surgical outcomes compared to surgery without reconstruction.
- It involved a comparison of 361 patients, identifying risk factors for complications, with results showing that higher body mass index, diabetes, and age were linked to increased risk of wound issues.
- Findings indicated that V-Y reconstruction significantly decreased postoperative complications, especially in patients with larger lesions, highlighting its benefits for those with significant surgical defects.
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population.
Eur J Cancer
September 2024
Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy. Electronic address:
Background: The TOPAZ-1 phase III trial showed a survival benefit with durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To understand this combination's real-world efficacy and tolerability, we conducted a global multicenter retrospective analysis of its first-line treatment outcomes.
Methods: We included patients with unresectable, locally advanced, or metastatic BTC treated with durvalumab, gemcitabine, and cisplatin at 39 sites in 11 countries (Europe, the United States, and Asia).
Evaluation of the benefit of indocyanine green as an educational and practical tool for ureteral identification in laparoscopic pelvic surgery: a cross-sectional study.
Minim Invasive Ther Allied Technol
October 2024
Lebanese American University Medical Center-Rizk Hospital, Beirut, Lebanon.
Background: Indocyanine green (ICG) is a visible near-infrared fluorescent dye. Several studies have reported its benefit in identifying important anatomical structures, tissue vascularization, and sentinel lymph nodes in the case of tumors. Studies have shown that ICG is critical and safe in gynecologic surgeries.
View Article and Find Full Text PDFEfficacy of letrozole for the treatment of tubal ectopic pregnancy: A meta-analysis.
Eur J Obstet Gynecol Reprod Biol
August 2024
Postgraduation Program in Health Sciences, Faculdade de Medicina do ABC/Centro Universitário FMABC, 09060-870 Santo André, Brazil.
Background: Tubal ectopic pregnancy (EP) is a life-threatening condition, especially if undiagnosed or misdiagnosed, tipically in low income countries and/or where women have limited access to health care. The current management protocol of tubal EP consists of either surgical management, or medical management with methotrexate. Recent studies, while few, have suggested that letrozole, an aromatase inhibitor, may play a role in the medical treatment of tubal EP.
View Article and Find Full Text PDFLong-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study.
Cancer Immunol Immunother
July 2024
Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino of Genova, Genova, Italy.
Background: Although nivolumab prolongs overall survival (OS) in pretreated patients with metastatic renal cell carcinoma (mRCC), underlining clinical and biological features of long-term responses are still to be determined. This study aims to investigate clinical and pathological characteristics of mRCC patients who achieved long-term responses during nivolumab treatment.
Materials And Methods: A retrospective analysis was performed on mRCC patients receiving nivolumab as second or further therapy line between May 2016 and January 2019 in 34 Italian Oncology Centres.
Characteristics, trends, and management of Penile cancer in the United States: A population-based study.
Urol Oncol
October 2024
Department of Urology, Rush University, Chicago, IL, USA. Electronic address:
Background: Penile cancer (PeCa) is a rare disease. HPV infection, smoking, phimosis, and lichen sclerosus represent well-known associated risk factors.
Objectives: Primary aim of our study is to evaluate the incidence and risk factors of PeCa and to outline the adopted diagnostic and therapeutic approaches.
Defining Global Benchmarks for Laparoscopic Right Posterior Sectionectomy/H67: An International Multicenter Study.
Ann Surg
June 2024
Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and National Cancer Centre Singapore, Singapore, Singapore.
Article Synopsis
- The study aimed to create global benchmark outcome indicators for laparoscopic right posterior sectionectomies (L-RPS/H67) to improve surgical standards.
- It analyzed data from 854 patients across 57 centers globally, establishing key performance benchmarks for low-risk cases based on specific outcome indicators.
- The findings set standard benchmarks for metrics like operation time and complication rates, serving as a reference for surgical auditing and improvement.
Robotic distal ureterectomy for high-risk distal ureteral urothelial carcinoma: a retrospective multicenter comparative analysis (ROBUUST 2.0 collaborative group).
Minerva Urol Nephrol
June 2024
Department of Urology, Rush University, Chicago, IL, USA -
Background: The role of kidney-sparing surgery in patients with high-risk upper urinary tract urothelial carcinoma is controversial. The present study aimed to assess oncological and functional outcomes of robot-assisted distal ureterectomy in patients with high-risk distal ureteral tumors.
Methods: The ROBUUST 2.
Impact of surgery on reproductive outcomes in women with deep endometriosis and proven presurgical infertility: Facts and controversies.
Best Pract Res Clin Obstet Gynaecol
September 2024
Unit of Obstetrics and Gynecology, "Paolo Giaccone" Hospital, 90127, Palermo, Italy; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127, Palermo, Italy. Electronic address:
Article Synopsis
- The management of infertility in women with deep endometriosis (DE) is contentious, with insufficient evidence regarding the link between infertility and the severity of DE as categorized by the rASRM stages.* -
- A systematic review encompassing 16 studies found that out of 947 infertile women who underwent surgery, 486 achieved pregnancy, indicating an average pregnancy rate of 51.3% and suggesting surgery may enhance reproductive outcomes, especially when coupled with assisted reproductive technology (ART).* -
- However, due to the varied data and lack of clarity on surgical outcomes relative to the location of DE, stronger conclusions cannot be drawn, highlighting the need for further research to optimize surgical strategies in relation to ART treatments.*
Sentinel node mapping, sentinel node mapping plus back-up lymphadenectomy, and lymphadenectomy in Early-sTage cERvical caNcer scheduled for fertilItY-sparing approach: The ETERNITY project.
Eur J Surg Oncol
September 2024
Gynecologic Oncologic Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy.
Objective: To investigate the safety of sentinel node mapping for patients with early-stage cervical cancer undergoing cervical conization plus nodal evaluation.
Methods: The ETERNITY project is a retrospective, multi-institutional study collecting data of patients with early-stage cervical cancer undergoing fertility-sparing treatment. Here, we compared outcomes related to three methods of nodal assessment: sentinel node mapping (SNM), SNM plus backup lymphadenectomy (SNM + LND); pelvic lymphadenectomy (LND).
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies.
ESMO Open
July 2024
Oncologia Medica A, Policlinico Umberto 1, La Sapienza Università Di Roma, Rome, Italy. Electronic address:
Background: Prostate cancer (PCa) treatments are associated with a detrimental impact on bone health (BH) and body composition. However, the evidence on these issues is limited and contradictory. This consensus, based on the Delphi method, provides further guidance on BH management in PCa.
View Article and Find Full Text PDFCOVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study.
BMC Cancer
June 2024
Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Article Synopsis
- Thymic epithelial tumors (TETs) are rare tumors often linked to immune issues, like Good's syndrome (GS), which increases mortality risk from infections.
- The study reviewed COVID-19 incidence and severity among TET patients from March 2020 to April 2023, noting that about 66% of participants contracted COVID-19, regardless of GS presence.
- Results showed a significant correlation between GS and increased COVID-19 severity, with 45% of GS patients experiencing higher severity scores compared to just 7.7% in patients without GS.
The use of oral nomegestrol acetate/estradiol in rapid and random start preparation of endometrium before office hysteroscopic polypectomies: A multicenter, prospective, randomized controlled trial.
Eur J Obstet Gynecol Reprod Biol
August 2024
Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy.
Objective: To evaluate the use of oral nomegestrol acetate/estradiol in random start rapid preparation of endometrium before office hysteroscopic polypectomy.
Study Design: Multicenter, prospective, randomized controlled trial.
Setting: University hospitals.
Corrigendum to "Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives" [Crit. Rev. Oncol./Hematol. 181 (2023) 103900].
Crit Rev Oncol Hematol
August 2024
Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Faculty of Medicine, University of Barcelona, Barcelona, Spain. Electronic address:
[Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
Lancet
June 2024
Endocrinology, IRCCS Policlinico San Martino and DiMI, University of Genova, Genoa, Italy.
Article Synopsis
- There are no established first-line treatments for higher grade gastroenteropancreatic neuroendocrine tumors (NETs), prompting a study on the effectiveness of Lu-DOTA-TATE (Lu-Dotatate) as a potential option.
- The NETTER-2 trial was a phase 3 study that randomized patients with advanced NETs to receive either Lu-Dotatate plus octreotide or high-dose octreotide alone, focusing on progression-free survival as the main outcome.
- Results showed that patients receiving Lu-Dotatate had a significantly longer median progression-free survival of 22.8 months compared to 8.5 months for those on high-dose octreotide, indicating Lu-Dotatate may
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
June 2024
Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.
Article Synopsis
- Tenosynovial giant cell tumour (TGCT) is a locally aggressive tumor with limited treatment options, leading this study to assess vimseltinib, a CSF1R inhibitor, in patients whose TGCT symptoms prevent surgery.
- The MOTION trial, a phase 3 randomized study, involved 123 adults from 35 hospitals globally, comparing vimseltinib to a placebo over 24 weeks, focusing on the objective response rate determined by independent radiological review.
- Results showed a significant objective response rate of 40% for vimseltinib compared to 0% for placebo, with most side effects being mild (grade 1 or 2), highlighting vimseltinib's
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
N Engl J Med
November 2024
From the Departments of Medical Oncology (C.U.B., M.W.L., L.L.H., J.M.L., S.M.P., J.B.A.G.H., K.A.T.N., J.V.T., S.W., A.M.-E., I.L.M.R.), Pathology (B.A.W.), Biometrics (M.L.-Y., A.T.A., L.G.G.-O.), Surgical Oncology (W.J.H., A.M.J.K., A.C.J.A.), Head and Neck Surgery (W.M.C.K., C.L.Z.), Radiology (B.A.S.), and Molecular Oncology and Immunology (J.B.A.G.H.), Netherlands Cancer Institute, and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam (A.J.M.E.), Amsterdam, the Departments of Medical Oncology (C.U.B., J.B.A.G.H., F.M.S., E.K.) and Otorhinolaryngology Head and Neck Surgery (C.L.Z.), Leiden University Medical Center, Leiden, the Departments of Medical Oncology (K.A.T.N., R.C.S., A.A.M.V.), Surgical Oncology (D.J.G., R.C.S.), and Radiology and Nuclear Medicine (A.A.M.V.), Erasmus Medical Center, Rotterdam, the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht (S.B.V., K.P.M.S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (R.R.), the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.), the Department of Medical Oncology, Medisch Spectrum Twente, Enschede (D.P.), the Department of Medical Oncology, Maxima Medical Center, Veldhoven (G.V.), the Department of Medical Oncology, Maastricht University Medical Center, GROW School for Oncology and Developmental Biology, Maastricht (M.J.B.A.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.B.), the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen (G.A.P.H.), and Isala Oncology Center, Isala Hospital, Zwolle (J.-W.B.G.) - all in the Netherlands; the Department of Hematology and Medical Oncology, University Clinic Regensburg, Regensburg, Germany (C.U.B.); Melanoma Institute Australia (R.A.S., A.M.M., R.P.M.S., N.G.M., M.G., S.N.L., A.S., T.E.P., K.F.S., R.V.R., S.C., J.S., M.A.R., A.C.J.A., M.S.C., G.V.L.), the Faculty of Medicine and Health (R.A.S., A.M.M., R.P.M.S., N.G.M., S.N.L., A.S., T.E.P., K.F.S., S.C., J.S., M.A.R., A.C.J.A., G.V.L.), and Charles Perkins Centre (R.A.S., G.V.L.), University of Sydney, the Departments of Tissue Pathology and Diagnostic Oncology (R.A.S., R.V.R.) and Melanoma and Surgical Oncology (R.P.M.S., T.E.P., K.F.S., S.C., J.S., M.A.R., A.C.J.A.), Royal Prince Alfred Hospital, NSW Health Pathology (R.A.S., R.V.R.), the Departments of Medical Oncology (A.M.M., G.V.L.) and Breast and Melanoma Surgery (A.S.), Royal North Shore and Mater Hospitals, and the Department of Radiology, Mater Hospital (R.K.), Sydney, Royal Prince Alfred Hospital, Institute of Academic Surgery, Camperdown, NSW (A.C.J.A.), the Division of Cancer Surgery, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC (D.E.G.), the Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, VIC (L.S., S.S.), Lake Macquarie Oncology, Lake Macquarie Private Hospital, the Department of Medical Oncology, Calvary Mater Hospital, and the Department of Medicine, School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (A.W.), the Department of Medical Oncology, Princess Alexandra Hospital, University of Queensland, Brisbane (V.A.), the Department of Medical Oncology, Fiona Stanley Hospital, Perth, WA (M.K.), the Department of Medical Oncology, Alfred Health, Melbourne, and the Department of Medicine, School of Translational Medicine, Monash University, Melbourne, VIC (M.C.A.), and the Department of Medical Oncology, Westmead Hospital and Blacktown, Sydney (M.S.C.) - all in Australia; the Melanoma Clinic, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (J.B.A.G.H.); the Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland (J.P., P.R.); the Department of Medical Oncology, Centre Léon Bérard, Lyon (M.A.-A.), Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP) Dermato-Oncology and Clinical Investigation Center, Cancer Institute AP-HP, Nord Paris Cité, INSERM Unité 976, Saint Louis Hospital, Paris (C.L.), and the Department of Medical Oncology, Gustave Roussy and Paris-Saclay University, Villejuif (C.R.) - all in France; the Department of Surgical Oncology, Angeles Clinic and Research Institute, Los Angeles (M.B.F.); and the Melanoma Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy (P.A.A.).
Article Synopsis
- In a study comparing neoadjuvant (before surgery) and adjuvant (after surgery) immunotherapy for stage III melanoma, neoadjuvant treatment showed greater effectiveness.
- The trial involved random assignment of 423 patients to receive either two cycles of neoadjuvant ipilimumab plus nivolumab followed by surgery, or surgery followed by 12 cycles of adjuvant nivolumab.
- Results indicated a significantly higher 12-month event-free survival rate in the neoadjuvant group (83.7%) compared to the adjuvant group (57.2%), with neoadjuvant therapy leading to better patient outcomes and more major pathological responses despite a higher incidence of severe adverse events.
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Lancet Gastroenterol Hepatol
August 2024
Division of Cancer Sciences, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK; Cholangiocarcinoma Foundation, Herriman, UT, USA.
Background: In the preplanned interim analysis of the TOPAZ-1 study, durvalumab plus gemcitabine-cisplatin significantly improved overall survival versus placebo plus gemcitabine-cisplatin in participants with advanced biliary tract cancer. We aimed to report updated overall survival and safety data from TOPAZ-1 with additional follow-up and data maturity beyond the interim analysis.
Methods: TOPAZ-1 was a phase 3, randomised, double-masked, placebo-controlled, global study done at 105 sites in 17 countries.
Application of novel algorithm on a retrospective series to implement the molecular classification for endometrial cancer.
Eur J Surg Oncol
July 2024
Clinic of Obstetrics and Gynecology, "Santa Maria della Misericordia" University Hospital, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy; PhD School in Biomedical Sciences, Gender Medicine, Child and Women Health. University of Sassari, Sassari, Sardinia, Italy.
Article Synopsis
- The study aimed to validate the Betella algorithm specifically for endometrial cancer patients, highlighting its impact on risk assessment according to 2020 ESGO/ESTRO/ESP guidelines.
- Conducted between March 2021 and March 2023, the research analyzed 102 patients’ molecular characteristics including p53 and mismatch repair protein levels, finding that 97% had complete analyses, which altered risk classifications for 11.1% of patients.
- The validation of the Betella algorithm allows for more accurate risk classification and can optimize resource use in treatment by reducing unnecessary molecular testing in a significant number of cases.
Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].
Lancet Reg Health Eur
July 2024
National Cancer Institute, IRCCS Fondazione G.Pascale, Naples, Italy.
[This corrects the article DOI: 10.1016/j.lanepe.
View Article and Find Full Text PDF